Hormonal
Traditional nontargeted weight management strategies (lifestyle changes, anti-obesity medications, and metabolic/bariatric surgery) are frequently inadequate for patients with highly penetrant monogenic or syndromic obesity caused by rare genetic variants in the melanocortin-4 receptor (MC4R) pathway.
If you have severe, early-onset obesity and insatiable hunger (hyperphagia) that persists despite strict dieting or surgery, standard approaches may not work because of a genetic disruption in your brain's hunger signals. You should seek genetic testing and specialized care to access targeted therapies (like setmelanotide) that address the root hormonal cause rather than just calories.
Critically, outcomes are variable, and traditional, nontargeted therapies are frequently inadequate in patients with highly penetrant obesity caused by rare genetic variants in key obesity pathogenesis pathways (ie, monogenic and syndromic obesities) [20–26].
Why this rating
Supported by multiple case reports, natural history studies, and retrospective analyses cited in the review.
Source
Differentiating monogenic and syndromic obesities from polygenic obesity: Assessment, diagnosis, and management
Angela Fitch et al. · Obesity Pillars · 2024
DOI 10.1016/j.obpill.2024.100110
More from this paper
- Targeted pharmacotherapy with MC4R agonists (specifically setmelanotide) is efficacious and safe for reducing body weight and hunger in patients with specific genetic causes of obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome (BBS).Good
- Metabolic and bariatric surgery (MBS) often results in substantial weight regain in patients with monogenic or syndromic obesity, particularly those with MC4R pathway variants, making it less effective than targeted pharmacotherapy for these groups.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →